Galactose-beta-1,3-N-acetylgalactosamine (Thomsen-Friedenreich antigen) (TF antigen)

Galactose-beta-1,3-N-acetylgalactosamine, widely known as the Thomsen-Friedenreich (TF) antigen or T antigen, is a disaccharide structure that serves as the core 1 foundation for O-linked glycans (GlyGen [3]). Under physiological conditions, this antigen is typically masked by sialic acid or further glycan extensions, making it cryptic and inaccessible to the immune system in healthy tissues. However, in approximately 80-90% of human carcinomas, including breast, colon, and prostate cancers, the TF antigen is truncated and overexpressed on the cell surface due to altered glycosyltransferase activity (Springer, 1984 [2]). This aberrant expression facilitates cancer cell adhesion to the endothelium and promotes metastasis by interacting with galectins, particularly Galectin-3. Consequently, the TF antigen is a significant target for cancer immunotherapy, including monoclonal antibodies like JAA-F11 and various carbohydrate-based vaccines designed to induce a targeted immune response against malignant cells (Heimburg-Molinaro et al., 2011 [1]). Its role as a pancarcinoma biomarker makes it a high-priority target for diagnostic and therapeutic development in oncology.

Other names

T antigenCD176Core 1 O-glycanGal-GalNAcThomsen-Friedenreich disaccharideTF alpha

Therapeutic strategies targeting the TF antigen primarily involve monoclonal antibodies that bind to the exposed disaccharide on the surface of malignant cells to induce antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) (Heimburg-Molinaro et al., 2011 [1]). Additionally, carbohydrate-based vaccines aim to stimulate the immune system to produce endogenous IgM and IgG antibodies that recognize and eliminate TF-positive tumor cells. Some agents also work by blocking the interaction between the TF antigen and circulating galectins (specifically Galectin-3), thereby inhibiting the formation of tumor cell clusters and their adhesion to the vascular endothelium, which effectively reduces metastatic potential (Springer, 1984 [2]).